Blog
RSS FeedPosted by Michael Wonder on 07 Oct 2024
Crossing the equity chasm: addressing a second valley of death in biomedical innovation
3 October 2024 - Traditionally, the term valley of death refers to the gap where advancements in basic research fail to ...
Posted by Michael Wonder on 05 Jun 2024
Why should the FDA focus on pragmatic clinical research?
3 June 2024 - Traditional randomised clinical trials have long been a key tool underpinning drug and device development. ...
Posted by Michael Wonder on 04 May 2023
Federal funding for discovery and development of costly HIV drugs was far more than previously estimated
1 May 2023 - In July 2012, tenofovir disoproxil fumarate-emtricitabine (Truvada) was approved by the FDA to prevent HIV infection. ...
Posted by Michael Wonder on 17 May 2022
Ethical considerations for the inclusion of patient reported outcomes in clinical research
17 May 2022 - An international consensus Delphi process was developed according to the Enhancing the Quality and Transparency of Health ...
Posted by Michael Wonder on 15 Nov 2021
Competing with, and learning from, China in the global pharmaceutical innovation race
15 November 2021 - President Joe Biden has promoted investment in technology based industries, including the life sciences, as a strategic ...
Posted by Michael Wonder on 17 Oct 2021
How much does it cost to research and develop a new drug? A systematic review and assessment
15 October 2021 - Debate over the viability of the current commercial research and development model is on-going. ...
Posted by Michael Wonder on 08 Jul 2021
House report: drug companies spent more on buybacks, dividends than research
8 July 2021 - House Democrats on Thursday released a report that found that the 14 leading drug companies paid ...
Posted by Michael Wonder on 25 Mar 2021
Taxpayers fund research and drug companies make a fortune
24 March 2021 - The pharmaceutical industry doesn’t want things to change, but Americans can have both lower prices and innovation. ...
Posted by Michael Wonder on 22 Oct 2020
Remdesivir’s hefty price tag ignores NIH investment in its creation
22 October 2020 - Throughout the Democratic presidential primary, candidates cast a spotlight on the broken U.S. health care system ...
Posted by Michael Wonder on 19 Aug 2020
Financing drug innovation in the US: current framework and emerging challenges
19 August 2020 - The current US drug innovation financing framework rests on the notion that a defined period of marketing ...
Posted by Michael Wonder on 06 Aug 2020
The world is spending nowhere near enough on a coronavirus vaccine
6 August 2020 - Far better to spend far too much. ...
Posted by Michael Wonder on 06 May 2020
Scientific research on the coronavirus is being released in a torrent
6 May 2020 - Will that change how science is published? ...
Posted by Michael Wonder on 07 Apr 2020
Scientists rush to find coronavirus cure—but it still isn’t fast enough
6 April 2020 - For drug companies, there is suddenly only one priority: the coronavirus. ...
Posted by Michael Wonder on 26 Mar 2020
Preserving clinical trial integrity during the coronavirus pandemic
25 March 2020 - Randomised clinical trials provide the highest-quality evidence for identifying therapies to help people attain longer and healthier ...
Posted by Michael Wonder on 25 Mar 2020
Treating COVID-19—off-label drug use, compassionate use, and randomised clinical trials during pandemics
24 March 2020 - In the 2014 Ebola outbreak, close to 30 000 individuals developed Ebola viral disease, and numerous therapies were ...